JAC Advance Access originally published online on July 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 247-252
© 2003 The British Society for Antimicrobial Chemotherapy
Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats
1 Faculty of Pharmacy, University of Montreal, Montreal, QC; 2 MDS Pharma Services, 2350 Cohen Street, St-Laurent (Montreal), QC, Canada
Received 4 October 2002; returned 6 December 2002; revised 9 April 2003; accepted 6 May 2003
Objective: To determine the pharmacokinetics and efficacy of tobramycin against pulmonary infections of Pseudomonas aeruginosa in rats after intratracheal administration of conventional and liposomal formulations.
Methods: Male Sprague–Dawley rats were inoculated with 106 cfu of a mucoid variant of P. aeruginosa (MIC of tobramycin for PA 508 = 1 mg/L) and tobramycin (conventional or liposomal formulations) was administered in single (490 µg) and multiple dose (490 µg during 4 days) experiments. Rats were killed at multiple time points to determine the residual cfu of P. aeruginosa and tobramycin amounts in lungs. Pharmacokinetic parameters were calculated using a two-compartment model with NONMEM.
Results: Mean (±S.D.) elimination half-life (t1/2ß) and pulmonary exposure (AUC) of the conventional formulation were 14.0 ±4.0 h and 663 ±89 µg×h/lungs, respectively. The pharmacokinetic profile of liposomal tobramycin was markedly different, with a longer t1/2ß (34.4 ±5 h, P < 0.05), resulting in an increased AUC (3890 ±560 µg×h/lungs, P < 0.05). 
2 analyses were carried out on cfu data distributed in the following categories: below 103, 103–105, and above 105 cfu. In the single dose experiments, approximately 90% of the observations were above 105 cfu for both formulations. Significant differences in cfu distribution were observed after multiple treatments, with approximately 10% of the observations falling below 103 cfu of P. aeruginosa for the conventional formulation versus 30% for the liposomal formulation.
Conclusion: The liposomal formulation of tobramycin promoted drug retention in lungs and improved its efficacy after multiple treatments.
Keywords: pharmacokinetics, efficacy, liposomal tobramycin, P. aeruginosa
* Corresponding author. Tel: +1-514-333-0042, ext. 4520; Fax: +1-514-333-7666; E-mail: Murray.Ducharme{at}mdsps.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Meers, M. Neville, V. Malinin, A. W. Scotto, G. Sardaryan, R. Kurumunda, C. Mackinson, G. James, S. Fisher, and W. R. Perkins Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections J. Antimicrob. Chemother., April 1, 2008; 61(4): 859 - 868. [Abstract] [Full Text] [PDF]
|
|